Solutions, Postsurgical Adhesion Inhibition

Definition : Solutions designed to act as a temporary barrier inhibiting postsurgical adhesion between tissues and organs. These solutions are applied to the surface of tissues and organs at the end of surgery, before surgical closure, and are typically resorbed by the body in a short period (e.g., several days). Postsurgical adhesion inhibition solutions are intended for use in pelvic and gynecological surgery, both in open and laparoscopic procedures.

Entry Terms : "Surgical Adhesion Barrier Solutions" , "Adhesion Inhibition Solutions" , "Adhesion Barrier Solutions" , "Scarring Inhibitors" , "Postsurgical Scarring Inhibitors" , "Barriers, Adhesion, Resorbable"

UMDC code : 20374

U.S.companies only
Suppress Subsidiary Companies

1-2 of 2 Match(es).

Anika Therapeutics Inc

Company Type: Parent

Anika Therapeutics is a pioneer in developing therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring polymer found throughout the body. HA enhances joint function and coats, protects, cushions and lubricates soft tissues. HA also is present in the skin, where it supports skin structure and elasticity. With more than 20 years of experience in HA technology, Anika is recognized worldwide as a provider of premium HA products that are effective, safe and long-lasting.

Confluent Surgical Inc

Company Type: Parent

1-2 of 2 Match(es).


Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs
Medical Product Guide Cancer Therapy Advisor Product Zone